Volume 3

Cover Page

1. Mannino, D.M. et al., "Surveillance for Asthma - United States, 1980–1999," Morbidity and Mortality Weekly Report, 51(SS01):1 - 13, March 29, 2002.

2. Goldman, J. et al., "Pharmacy Benefits and the Use of Drugs by the Chronically Ill," The Journal of the American Medical Association, May 19, 2004; 291:2344 - 2350, 2349.

3. United Nations Environmental Programme, "Production and Consumption of Ozone-Depleting Substances 1986 - 2000," 2003.

4. Weiss, K.B. et al., "Trends in the Costs of Illness for Asthma in the United States,1985 - 1994," Journal of Allergy and Clinical Immunology, 106(3):493 - 499, September 2000.

5. Mannino, D.M. et al., "Chronic Obstructive Pulmonary Disease Surveillance - United States, 1971 - 2000,"
Morbidity and Mortality Weekly Report, 51(SS06):1 - 16, August 2, 2002.

6. Food and Drug Administration, Center for Drug Evaluation and Research, Approved Drug Products with Therapeutic Equivalent Evaluations, 23rd Edition, 2003.

7. Drug Topics, Red Book, Thomson Medical Economics, 2002.

8. Rozek, R.P., and E.R. Bishko, "The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone - Depleting Substance," National Economic Research Associates, September 8, 2003.

9. Ringel J.S. et al., "The Elasticity of Demand for Health Care," National Defense Research Institute, Rand Health, 2002.

10. Goldman, Dana, private communication, May 29, 2004.

11. Caves, R.E. et al., "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry," Brookings Papers on Economic Activity, Microeconomics, 1991.

12. Bureau of Census, "Health Insurance Coverage: 2001," Current Population Reports, U.S. Department of Commerce, September 2002.

13. Communication between Mr. Thomas Bizzaro, Vice-President of the National Council of Prescription Drug Plans, and Mr. Steven A. Tucker, Food and Drug Administration, June 23, 2003.

14. Suissa, S. et al., "Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma," New England Journal of Medicine, 343(5):332 - 336, 2000.

15. Congressional Budget Office, "How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry," July 1998.